Interneuron Pharmaceuticals
Executive Summary
Acquires worldwide rights to several melatonin-modulating compounds from Whitby Research Inc., a subsidary of Ethyl Corp. Interneuron claims that the compounds have potential applications in the treatment of depression, fertility and sleep disorders, jet lag and chronic fatigue syndrome. According to Charles Casamento, president and CEO of Interneuron, the company "is most interested in depression and insomnia" applications of the compounds. Casamento says that clinical trials for any of the compounds are "a year and a half to two years away".